Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours.
Anna
A
Koumarianou
Stavroula
S
Antoniou
George
G
Kanakis
Nikolaos
N
Economopoulos
Dimitra
D
Rontogianni
Anastasios
A
Ntavatzikos
Nikolaos
N
Tsavaris
Dimitrios
D
Pectasides
George
G
Dimitriadis
Gregory
G
Kaltsas
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018358:Neuroendocrine Tumors / Q000188:drug therapy*; D015282:Octreotide / Q000008:administration & dosage; D000077204:Temozolomide
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D018906:Antineoplastic Agents, Alkylating; D018931:Antineoplastic Agents, Hormonal; D000068258:Bevacizumab; D003606:Dacarbazine; D015282:Octreotide; D000077204:Temozolomide